Age-related changes in renal and hepatic cellular mechanisms associated with variations in rat serum thyroid hormone levels

2008 ◽  
Vol 294 (6) ◽  
pp. E1160-E1168 ◽  
Author(s):  
Elena Silvestri ◽  
Assunta Lombardi ◽  
Pieter de Lange ◽  
Luigi Schiavo ◽  
Antonia Lanni ◽  
...  
Keyword(s):  
Thyroid Hormone ◽  
Total Protein ◽  
Protein Level ◽  
Monocarboxylate Transporter ◽  
Type I ◽  
Peripheral Tissues ◽  
Protein Levels ◽  
Age Related ◽  
Liver And Kidney ◽  
Age Related Changes

Aging is associated with changes in thyroid gland physiology. Age-related changes in the contribution of peripheral tissues to thyroid hormone serum levels have yet to be systematically assessed. Here, we investigated age-related alterations in the contributions of the liver and kidney to thyroid hormone homeostasis using 6-, 12-, and 24-mo-old male Wistar rats. A significant and progressive decline in plasma thyroxine occurred with age, but triiodothyronine (T3) was decreased only at 24 mo. This was associated with an unchanged protein level of the thyroid hormone transporter monocarboxylate transporter 8 (MCT8) in the kidney and with a decreased MCT8 level in the liver at 24 mo. Hepatic type I deiodinase (D1) protein level and activity declined progressively with age. Renal D1 levels were decreased at both 12 and 24 mo but D1 activity was decreased only at 24 mo. In the liver, no changes occurred in thyroid hormone receptor (TR) TRα1, whereas a progressive increase in TRβ1 occurred at both mRNA and total protein levels. In the kidney, both TRα1 and TRβ1 mRNA and total protein levels were unchanged between 6 and 12 mo but increased at 24 mo. Interestingly, nuclear TRβ1 levels were decreased in both liver and kidney at 12 and 24 mo, whereas nuclear TRα1 levels were unchanged. Collectively, our data show differential age-related changes among hepatic and renal MCT8 and D1 and TR expressions, and they suggest that renal D1 activity is maintained with age to compensate for the decrease in hepatic T3 production.

scholarly journals Age-Related Changes in Molecular and Whole Muscle Function: Role of Fat Content?

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 141-141
Author(s):  
Joseph Gordon III ◽  
Nicholas Remillard ◽  
Chad Straight ◽  
Rajakumar Nagarajan ◽  
Bruce Damon ◽  
...  
Keyword(s):  
Older Adults ◽  
Molecular Mechanisms ◽  
Fat Content ◽  
Fat Deposition ◽  
Muscle Size ◽  
Type I ◽  
Contraction Velocity ◽  
Age Related ◽  
Whole Muscle ◽  
Age Related Changes

Abstract Decreases in muscle size and function are a general consequence of old age; the precise mechanisms of these changes remain unclear. Recent studies suggest that fat deposition in muscle may also contribute to dysfunction in older adults. Fat content was quantified in the quadriceps, and its effects on function in healthy young (21-45 y) and older (65-75 y) men and women (n=44) of comparable physical activity were compared. A subset of the young matched with the older group for muscle fat content were also examined. Peak fat-free whole muscle cross-sectional area (mCSA; cm2), volume (MV; cm3), fat content (fat fraction, FF; %), specific torque (Nm/mCSA) and peak contraction velocity (Nm∙s-1) were determined using fat-water magnetic resonance imaging and dynamometry (0-300□∙s-1). To examine potential molecular mechanisms of muscle weakness, vastus lateralis biopsies were obtained (n=31) and cross-bridge kinetics of type I and II fibers were determined. FF was higher in older adults than young (8.4±1.2% (SE), 7.6±1.4; p=0.03), while mCSA (48.9±10.4 vs. 64.2±17.3), MV (1536±532 vs. 2112±708), specific torque (2.6±0.4 vs. 3.2±0.4), and peak voluntary contraction velocity (422±20 vs. 441±23) were lower in older than young (p<0.01). Type II fiber myosin attachment rate was slower and attachment time longer in older muscle (p<0.017), providing a potential mechanism for the slowing of peak contraction velocity with age. Notably, differences at the whole muscle and molecular levels remained for the subset of young and older groups matched for FF, suggesting that fat deposition in muscle does not exacerbate age-related changes in function.

scholarly journals AMIODARON SEBAGAI OBAT ANTI ARITMIA DAN PENGARUHNYA TERHADAP FUNGSI TIROID

2013 ◽  
Vol 3 (2) ◽  
Author(s):  
Starry H. Rampengan
Keyword(s):  
Thyroid Hormone ◽  
Thyroid Gland ◽  
Thyroid Function ◽  
Hormone Replacement ◽  
Type I ◽  
Peripheral Tissues ◽  
Hormone Synthesis ◽  
Thyroid Hormone Metabolism ◽  
Serum T4 ◽  
Life Threatening

Abstract: Amiodarone is a highly effective anti-arrhythmic agent used in certain arrhythmias from supraventricular tachycardia to life-threatening ventricular tachycardia. Its use is associated with numerous side-effects that could deteriorate a patient’s condition. Consequently, a clinician should consider the risks and benefits of amiodarone before initiating the treatment.The thyroid gland is one of the organs affected by amiodarone. Amiodarone and its metabolite desethyl amiodaron induce alterations in thyroid hormone metabolism in the thyroid gland, peripheral tissues, and probably also in the pituitary gland. These actions result in elevations of serum T4 and rT3 concentrations, transient increases in TSH concentrations, and decreases in T3 concentrations. Both hypothyroidism and hyperthyroidism are prone to occur in patients receiving amiodarone. Amiodarone-induced hypothyroidism (AIH) results from the inability of the thyroid to escape from the Wolff-Chaikoff effect and is readily managed by either discontinuation of amiodarone or thyroid hormone replacement. Amiodarone-induced thyrotoxicosis (AIT) may arise from either iodine-induced excessive thyroid hormone synthesis (type I, usually with underlying thyroid abnormality), or destructive thyroiditis with release of preformed hormones (type II, commonly with apparently normal thyroid glands). Therefore, monitoring of thyroid function should be performed in all amiodarone-treated patients to facilitate early diagnosis and treatment of amiodarone-induced thyroid dysfunction. Key words: Amiodarone, thyroid function, side effect, management, monitoring.     Abstrak: Amiodaron adalah obat antiaritmia yang cukup efektif dalam menangani beberapa keadaaan aritmia mulai dari supraventrikuler takikardia sampai takikardia ventrikuler yang mengancam kehidupan. Namun penggunaan obat ini ternyata menimbulkan efek samping pada organ lain yang dapat menimbulkan perburukan keadaan pasien. Sehingga, dalam penggunaan amiodaron, klinisi juga harus menimbang keuntungan dan kerugian yang ditimbulkan oleh obat ini. Salah satu organ yang dipengaruhi oleh amiodaron adalah kelenjar tiroid. Amiodaron dan metabolitnya desetil amiodaron memengaruhi hormon tiroid pada kelenjar tiroid, jaringan perifer, dan mungkin pada pituitari. Aksi amiodaron ini menyebabkan peningkatan T4, rT3 dan TSH, namun menurunkan kadar T3. Hipotiroidisme dan tirotoksikosis dapat terjadi pada pasien yang diberi amiodaron. Amiodarone-induced hypothyroidism (AIH) terjadi karena ketidakmampuan tiroid melepaskan diri dari efek Wolff Chaikof, dan dapat ditangani dengan pemberian  hormon substitusi T4 atau penghentian amiodaron. Amiodarone-induced thyrotoxicosis (AIT) terjadi karena sintesis hormon tiroid yang berlebihan yang diinduksi oleh iodium (tipe I, biasanya sudah mempunyai kelainan tiroid sebelumnya) atau karena tiroiditis destruktif yang disertai pelepasan hormon tiroid yang telah terbentuk (tipe II, biasanya dengan kelenjar yang normal). Pemantauan fungsi tiroid seharusnya dilakukan pada semua pasien yang diberi amiodaron untuk memfasilitasi diagnosis dan terapi yang dini terjadinya  disfungsi tiroid yang diinduksi amiodaron. Kata Kunci: Amiodaron, fungsi tiroid, efek samping, penanganan, pemantauan.

scholarly journals Effective Cellular Uptake and Efflux of Thyroid Hormone by Human Monocarboxylate Transporter 10

2008 ◽  
Vol 22 (6) ◽  
pp. 1357-1369 ◽  
Author(s):  
Edith C. H. Friesema ◽  
Jurgen Jansen ◽  
Jan-willem Jachtenberg ◽  
W. Edward Visser ◽  
Monique H. A. Kester ◽  
...  
Keyword(s):  
Amino Acids ◽  
Plasma Membrane ◽  
Thyroid Hormone ◽  
Cellular Uptake ◽  
Aromatic Amino Acids ◽  
Significant Inhibition ◽  
Monocarboxylate Transporter ◽  
Strong Increase ◽  
Type I ◽  
Hormone Binding Protein

Abstract Cellular entry of thyroid hormone is mediated by plasma membrane transporters, among others a T-type (aromatic) amino acid transporter. Monocarboxylate transporter 10 (MCT10) has been reported to transport aromatic amino acids but not iodothyronines. Within the MCT family, MCT10 is most homologous to MCT8, which is a very important iodothyronine transporter but does not transport amino acids. In view of this paradox, we decided to reinvestigate the possible transport of thyroid hormone by human (h) MCT10 in comparison with hMCT8. Transfection of COS1 cells with hMCT10 cDNA resulted in 1) the production of an approximately 55 kDa protein located to the plasma membrane as shown by immunoblotting and confocal microscopy, 2) a strong increase in the affinity labeling of intracellular type I deiodinase by N-bromoacetyl-[125I]T3, 3) a marked stimulation of cellular T4 and, particularly, T3 uptake, 4) a significant inhibition of T3 uptake by phenylalanine, tyrosine, and tryptophan of 12.5%, 22.2%, and 51.4%, respectively, and 5) a marked increase in the intracellular deiodination of T4 and T3 by different deiodinases. Cotransfection studies using the cytosolic thyroid hormone-binding protein μ-crystallin (CRYM) indicated that hMCT10 facilitates both cellular uptake and efflux of T4 and T3. In the absence of CRYM, hMCT10 and hMCT8 increased T3 uptake after 5 min incubation up to 4.0- and 1.9-fold, and in the presence of CRYM up to 6.9- and 5.8-fold, respectively. hMCT10 was less active toward T4 than hMCT8. These findings establish that hMCT10 is at least as active a thyroid hormone transporter as hMCT8, and that both transporters facilitate iodothyronine uptake as well as efflux.

Age-Related Changes in Scleral Material Properties of the Monkey Eye

2008 ◽  
Author(s):  
Michaël J. A. Girard ◽  
Jun-Kyo F. Suh ◽  
Michael Bottlang ◽  
Claude F. Burgoyne ◽  
J. Crawford Downs
Keyword(s):  
Intraocular Pressure ◽  
Material Properties ◽  
Lamina Cribrosa ◽  
Collagen Fibers ◽  
Visual Signals ◽  
Type I ◽  
Retinal Ganglion ◽  
Age Related ◽  
The Brain ◽  
Age Related Changes

The sclera is the outer shell and principal load-bearing tissue of the eye, which consists primarily of avascular lamellae of collagen fibers. Ninety percent of the collagen fibers in the sclera are Type I, which provide the eye with necessary mechanical strength to sustain intraocular pressure (IOP). In the posterior sclera, there is a fenestrated canal, called the optic nerve head (ONH), through which the retinal ganglion cell axons pass transmitting visual signals from the retina to the brain. The opening of the ONH is structurally supported by a fenestrated connective tissue called the lamina cribrosa.

Specificity and age-related changes of antibodies to collagen type i in normal human sera

Autoimmunity ◽  
1994 ◽  
Vol 17 (3) ◽  
pp. 257-258 ◽  
Author(s):  
G. Nicoloff ◽  
D. Valcova ◽  
S. Baydanoff
Keyword(s):  
Collagen Type ◽  
Collagen Type I ◽  
Type I ◽  
Age Related ◽  
Human Sera ◽  
Normal Human ◽  
Age Related Changes

Maximal lactate steady state declines during the aging process

2003 ◽  
Vol 95 (6) ◽  
pp. 2576-2582 ◽  
Author(s):  
Craig O. Mattern ◽  
Margaret J. Gutilla ◽  
Darrin L. Bright ◽  
Timothy E. Kirby ◽  
Kenneth W. Hinchcliff ◽  
...  
Keyword(s):  
Steady State ◽  
Exercise Intensity ◽  
Citrate Synthase ◽  
Age Groups ◽  
Type I ◽  
Training Intensity ◽  
Maximal Lactate Steady State ◽  
Age Related ◽  
Competitive Cyclists ◽  
Age Related Changes

Increased participation of aged individuals in athletics warrants basic research focused on delineating age-related changes in performance variables. On the basis of potential age-related declines in aerobic enzyme activities and a shift in the expression of myosin heavy chain (MHC) isoforms, we hypothesized that maximal lactate steady-state (MLSS) exercise intensity would be altered as a function of age. Three age groups [young athletes (YA), 25.9 ± 1.0 yr, middle-age athletes (MA), 43.2 ± 1.0 yr, and older athletes (OA), 64.6 ± 2.7 yr] of male, competitive cyclists and triathletes matched for training intensity and duration were studied. Subjects performed a maximal O2 consumption (V̇o2 max) test followed by a series of 30-min exercise trials to determine MLSS. A muscle biopsy of the vastus lateralis was procured on a separate visit. There were differences ( P < 0.05) in V̇o2 max among all age groups (YA = 67.7 ± 1.2 ml · kg-1 · min-1, MA = 56.0 ± 2.6 ml · kg-1 · min-1, OA = 47.0 ± 2.6 ml · kg-1 · min-1). When expressed as a percentage of V̇o2 max, there was also an age-related decrease ( P < 0.05) in the relative MLSS exercise intensity (YA = 80.8 ± 0.9%, MA = 76.1 ± 1.4%, OA = 69.9 ± 1.5%). There were no significant age-related changes in citrate synthase activity or MHC isoform profile. The hypothesis is supported as there is an age-related decline in MLSS exercise intensity in athletes matched for training intensity and duration. Although type I MHC isoform, combined with age, is helpful in predicting ( r = 0.76, P < 0.05) relative MLSS intensity, it does not explain the age-related decline in MLSS.

scholarly journals Characterization of Human Iodothyronine Sulfotransferases1

1999 ◽  
Vol 84 (4) ◽  
pp. 1357-1364 ◽  
Author(s):  
Monique H. A. Kester ◽  
Ellen Kaptein ◽  
Thirza J. Roest ◽  
Caren H. van Dijk ◽  
Dick Tibboel ◽  
...  
Keyword(s):  
Thyroid Hormone ◽  
Human Liver ◽  
Type I ◽  
Dependent Manner ◽  
Concentration Dependent Manner ◽  
Iodothyronine Deiodinase ◽  
Liver Cytosol ◽  
Thyroid Hormone Metabolism ◽  
Liver And Kidney ◽  
Phenol Sulfotransferase

Sulfation is an important pathway of thyroid hormone metabolism that facilitates the degradation of the hormone by the type I iodothyronine deiodinase, but little is known about which human sulfotransferase isoenzymes are involved. We have investigated the sulfation of the prohormone T4, the active hormone T3, and the metabolites rT3 and 3,3′-diiodothyronine (3,3′-T2) by human liver and kidney cytosol as well as by recombinant human SULT1A1 and SULT1A3, previously known as phenol-preferring and monoamine-preferring phenol sulfotransferase, respectively. In all cases, the substrate preference was 3,3′-T2 &gt;&gt; rT3 &gt; T3 &gt; T4. The apparent Km values of 3,3′-T2 and T3 [at 50 μmol/L 3′-phosphoadenosine-5′-phosphosulfate (PAPS)] were 1.02 and 54.9μ mol/L for liver cytosol, 0.64 and 27.8 μmol/L for kidney cytosol, 0.14 and 29.1 μmol/L for SULT1A1, and 33 and 112 μmol/L for SULT1A3, respectively. The apparent Km of PAPS (at 0.1μ mol/L 3,3′-T2) was 6.0 μmol/L for liver cytosol, 9.0μ mol/L for kidney cytosol, 0.65 μmol/L for SULT1A1, and 2.7μ mol/L for SULT1A3. The sulfation of 3,3′-T2 was inhibited by the other iodothyronines in a concentration-dependent manner. The inhibition profiles of the 3,3′-T2 sulfotransferase activities of liver and kidney cytosol obtained by addition of 10 μmol/L of the various analogs were better correlated with the inhibition profile of SULT1A1 than with that of SULT1A3. These results indicate similar substrate specificities for iodothyronine sulfation by native human liver and kidney sulfotransferases and recombinant SULT1A1 and SULT1A3. Of the latter, SULT1A1 clearly shows the highest affinity for both iodothyronines and PAPS, but it remains to be established whether it is the prominent isoenzyme for sulfation of thyroid hormone in human liver and kidney.

Sign in / Sign up

Export Citation Format

Share Document